Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Plasma cell 1Lymphoid 1Genitourinary 1Gastrointestinal 1Classical hematology 1Breast 1

Conditions

Colorectal Neoplasms 34Carcinoma, Non-Small-Cell Lung 26Breast Neoplasms 25Lung Neoplasms 24Colonic Neoplasms 18Head and Neck Neoplasms 16Rectal Neoplasms 14Sarcoma 10Prostatic Neoplasms 10Neoplasm Metastasis 9Pancreatic Neoplasms 8Neoplasms 7Mouth Neoplasms 7Melanoma 7Esophageal Neoplasms 7Ovarian Neoplasms 6Glioblastoma 6Adenomatous Polyposis Coli 6Precancerous Conditions 5Neuroblastoma 5Liver Neoplasms 5Central Nervous System Neoplasms 5Carcinoma 5Unspecified Adult Solid Tumor, Protocol Specific 4Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Recurrence 4Oropharyngeal Neoplasms 4Laryngeal Neoplasms 4Hypopharyngeal Neoplasms 4

Interventions

Cyclophosphamide 62fludarabine phosphate 55Peripheral Blood Stem Cell Transplantation 44Tacrolimus 41Busulfan 40ruxolitinib 39Mycophenolic Acid 36Whole-Body Irradiation 32Antilymphocyte Serum 29Methotrexate 27Cyclosporine 27fludarabine 24Melphalan 19Filgrastim 19Radiotherapy 15Methylprednisolone 13thymoglobulin 12Etoposide 12Cord Blood Stem Cell Transplantation 12Azacitidine 12Stem Cell Transplantation 11Sirolimus 1111-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 10Decitabine 9Specimen Handling 8Prednisone 8Cytarabine 8Imatinib Mesylate 7Granulocyte Colony-Stimulating Factor 7Flow Cytometry 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Primary Myelofibrosis × Celecoxib × Clear all
NCT04041050 2025-02-14

A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

AbbVie

Phase 1 Active not recruiting
85 enrolled
MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Neoplasms, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡